ATE246690T1 - Thiazolopyrimidine verwendbar als tnf-alpha inhibitoren - Google Patents

Thiazolopyrimidine verwendbar als tnf-alpha inhibitoren

Info

Publication number
ATE246690T1
ATE246690T1 AT00935991T AT00935991T ATE246690T1 AT E246690 T1 ATE246690 T1 AT E246690T1 AT 00935991 T AT00935991 T AT 00935991T AT 00935991 T AT00935991 T AT 00935991T AT E246690 T1 ATE246690 T1 AT E246690T1
Authority
AT
Austria
Prior art keywords
thiazolopyrimidines
tnf
alpha inhibitors
inhibitors
alpha
Prior art date
Application number
AT00935991T
Other languages
English (en)
Inventor
Dennis A Carson
Howard B Cottam
Lynn Deng
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE246690T1 publication Critical patent/ATE246690T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
AT00935991T 1999-05-17 2000-05-16 Thiazolopyrimidine verwendbar als tnf-alpha inhibitoren ATE246690T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/313,048 US6930101B1 (en) 1999-05-17 1999-05-17 Thiazolopyrimidines useful as TNFα inhibitors
PCT/US2000/013410 WO2000069861A1 (en) 1999-05-17 2000-05-16 THIAZOLOPYRIMIDINES USEFUL AS TNFα INHIBITORS

Publications (1)

Publication Number Publication Date
ATE246690T1 true ATE246690T1 (de) 2003-08-15

Family

ID=23214152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935991T ATE246690T1 (de) 1999-05-17 2000-05-16 Thiazolopyrimidine verwendbar als tnf-alpha inhibitoren

Country Status (8)

Country Link
US (2) US6930101B1 (de)
EP (1) EP1187838B1 (de)
JP (1) JP2003520768A (de)
AT (1) ATE246690T1 (de)
AU (1) AU774981B2 (de)
CA (1) CA2370066A1 (de)
DE (1) DE60004362T2 (de)
WO (1) WO2000069861A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) * 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
US7223398B1 (en) 1999-11-15 2007-05-29 Dynavax Technologies Corporation Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
SG160336A1 (en) 2005-03-04 2010-04-29 Dynavax Tech Corp Vaccines comprising oligonucleotides having immunostimulatory sequences (iss) wherein the iss are conjugated to antigens and stabilized by buffer conditions and further excipients
KR101709141B1 (ko) 2008-01-25 2017-02-22 브이티브이 테라퓨틱스 엘엘씨 ＴＮＦ-α 합성의 조절자 및 ＰＤＥ4 억제제로서 3고리 화합물
TWI908838B (zh) 2020-07-28 2025-12-21 美商Ｖｔｖ治療有限責任公司 喹啉衍生物的鹽酸鹽的結晶形式

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3127402A (en) 1964-03-31 Y-oxopteridine derivatives
US3660405A (en) 1969-08-13 1972-05-02 Baxter Laboratories Inc Thiazolopyrimidines
US3594378A (en) 1969-10-24 1971-07-20 Ayerst Mckenna & Harrison Thiazolopyrimidine derivatives and preparation thereof
US3919201A (en) 1970-09-30 1975-11-11 Lilly Industries Ltd 2-({62 -Aminoacryloyl)iminobenzothiazolines
US4041167A (en) 1976-01-19 1977-08-09 Diamond Shamrock Corporation Antiinflammatory imidazothiazoles
US4224334A (en) 1976-01-19 1980-09-23 Diamond Shamrock Corporation Antiinflammatory imidazothiazoles and thiazolopyrimidines
US4111693A (en) 1976-12-22 1978-09-05 Eastman Kodak Company Multilayer aggregate photoconductive elements
US4175961A (en) 1976-12-22 1979-11-27 Eastman Kodak Company Multi-active photoconductive elements
US4160768A (en) 1976-12-29 1979-07-10 Diamond Shamrock Corporation Anti-inflammatory 3-benzofuranyl imidazothiazole
US4077955A (en) 1977-02-17 1978-03-07 E. R. Squibb & Sons, Inc. Amino derivatives of 1,2,3,4-tetrahydro-2-oxopyrido[2,2-b]-pyrazine carboxylic acids and esters
US4510141A (en) 1982-09-13 1985-04-09 Ciba-Geigy Corporation Tricyclic polyazaheterocycles for treating depression or anxiety
JPS5976086A (ja) 1982-09-20 1984-04-28 ザ　ウエルカム　フアウンデ−シヨン　リミテツド プテリジン化合物
GB8318833D0 (en) 1983-07-12 1983-08-10 Wellcome Found Chemical compounds
US4593095A (en) 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4769377A (en) 1983-02-18 1988-09-06 The Johns Hopkins University Adenosine receptor antagonists
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
FR2574408B1 (fr) 1984-12-12 1987-01-30 Rhone Poulenc Sante Procede de preparation d'isomeres optiques de thiazolo(3,2-a) pyrimidines, les nouveaux isomeres ainsi obtenus, les compositions pharmaceutiques qui les contiennent et les intermediaires pour mettre en oeuvre ce procede
DK337086A (da) 1985-08-12 1987-02-13 Hoffmann La Roche Benzimidazolderivater
US4794114A (en) 1986-08-19 1988-12-27 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
US4778806A (en) 1986-08-19 1988-10-18 Smithkline Beckman Corporation Inhibition of interleukin-1 production by monocytes and/or macrophages
IT1199320B (it) 1986-12-16 1988-12-30 Malesci Sas 8-azaxantine alchilaminoalchil o eterociclilalchil sostituite sul nucleo triazolico,loro sali fisiologicamente accettabili,loro composizioni farmaceutiche ad attivita'antibroncospastica e relativo procedimento di preparazione
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
DE3821711A1 (de) 1988-06-28 1990-02-08 Bayer Ag Thiazolopyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1991000092A1 (en) 1989-06-13 1991-01-10 Smithkline Beecham Corporation Inhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophages
EP0493682A3 (en) 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
EP0490181A1 (de) 1990-11-30 1992-06-17 Hoechst-Roussel Pharmaceuticals Incorporated Verwendung von Xanthinen zur Herstellung eines Medikaments mit immunsuppressiver Wirkung
WO1992010190A1 (en) 1990-12-13 1992-06-25 Smithkline Beecham Corporation Novel csaids
JP3566719B2 (ja) 1991-05-24 2004-09-15 フレッド ハッチンソン キャンサー リサーチ センター 外来性刺激に対する細胞性応答の調整
DE4131038A1 (de) 1991-09-20 1993-04-01 Basf Ag Substituierte 3-phenylurazile
US5656644A (en) 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
AU3725893A (en) 1992-02-21 1993-09-13 Smithkline Beecham Corporation TNF inhibitors
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
US5288721A (en) 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
TW274550B (de) 1992-09-26 1996-04-21 Hoechst Ag
US5641783A (en) 1993-11-12 1997-06-24 Cell Therapeutics, Inc. Substituted amino alcohol compounds
NO941135L (no) 1993-04-01 1994-10-03 Daiichi Seiyaku Co Tiazolpyrimidin derivater
US5670506A (en) 1993-04-05 1997-09-23 Cell Therapeutics, Inc. Halogen, isothiocyanate or azide substituted xanthines
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5366978A (en) 1993-11-03 1994-11-22 Mk Medical Ltd. Treatment for Kawasaki disease
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
JP3273108B2 (ja) 1994-09-21 2002-04-08 アサヒビール株式会社 新規ピリド〔２，３−ｄ〕ピリミジン誘導体及びその製造方法
US5843943A (en) 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
CA2208580A1 (en) 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5521181A (en) 1995-01-27 1996-05-28 Abbott Laboratories Bicyclic substituted hexahydrobenz[e]isoindole α-1 adrenergic antagonists
US5792767A (en) 1995-01-27 1998-08-11 Abbott Laboratories Bicyclic substituted hexahydrobenz e! isoindole alpha-1 adrenergic antagonists
US5753664A (en) 1995-03-16 1998-05-19 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
CA2502764A1 (en) 1995-08-22 1997-03-06 Japan Tobacco Inc. Amide compounds
TR199801361T2 (xx) 1996-01-11 1998-10-21 Smithkline Beecham Corporation Yeni ikameli imidazol bile�imleri.
AP9700912A0 (en) 1996-01-11 1997-01-31 Smithkline Beecham Corp Novel cycloalkyl substituted imidazoles
JP2001508395A (ja) 1996-01-11 2001-06-26 スミスクライン・ビーチャム・コーポレイション 新規シクロアルキル置換イミダゾール
GB9623859D0 (en) 1996-11-15 1997-01-08 Chiroscience Ltd Novel compounds
AU2003253165A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2005037845A1 (en) * 2003-10-17 2005-04-28 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors

Also Published As

Publication number Publication date
DE60004362T2 (de) 2004-02-26
JP2003520768A (ja) 2003-07-08
WO2000069861A1 (en) 2000-11-23
CA2370066A1 (en) 2000-11-23
EP1187838B1 (de) 2003-08-06
US7098216B2 (en) 2006-08-29
AU774981B2 (en) 2004-07-15
US6930101B1 (en) 2005-08-16
US20050065116A1 (en) 2005-03-24
AU5136700A (en) 2000-12-05
DE60004362D1 (de) 2003-09-11
EP1187838A1 (de) 2002-03-20

Similar Documents

Publication Publication Date Title
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ATE231872T1 (de) Thiazolopyrimidinderivate
MY135233A (en) N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
BR0108396A (pt) Derivados de pirimidina-4-0na como inibidores de ldl-pla(2)
DE69907977D1 (de) Pyrrolobenzodiazepine
NO952398L (no) Pyrrolpyrimidiner som CRF antagonister
BG106900A (en) N-(5,7-DIMETHOXY[1,2,4[TRIAZOLO[1,5-a] PYRIMIDIN-2-YL) ARYLSULFONAMIDE COMPOUNDS AND THEIR USE AS HERBICIDES
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
NO992492L (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
PT1473036E (pt) Solvato de hemitartarato de zolpidem
NO20035025L (no) Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet.
DK1257176T3 (da) Anvendelse af syrestabile proteaser i dyrefoder
ATE234840T1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder - thione inhibitoren von phosphodiesterasen iv
AU3938802A (en) Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
BR0009767A (pt) Agentes inibitórios e quimiotáticos derivados de osteopontina e seus usos
NO20031860L (no) Kahalalid F
MXPA03003923A (es) Compuestos de n-([1,2,4]triazoloazinil)tiofensulfonamida como herbicidas.
MY136297A (en) Piperazine derivatives having sst1 antagonistic activity
ATE259813T1 (de) Triazolopyrimidinderivate
DE60004362D1 (de) Thiazolopyrimidine verwendbar als TNF-Alpha Inhibitoren
BR0110902A (pt) Inibidores de mmp-9/mmp-2
BR0316544A (pt) Compostos calcilìticos
NO20005548L (no) Mykobakterieinhibitorer
BG106599A (en) Wood treatment

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties